metformin and fenofibrate

metformin has been researched along with fenofibrate in 45 studies

Research

Studies (45)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (40.00)29.6817
2010's26 (57.78)24.3611
2020's1 (2.22)2.80

Authors

AuthorsStudies
Agarwal, SC; Chander, R; Khaliq, T; Narender, T; Papi Reddy, K; Prathipati, P; Puri, A; Raj, K; Shweta, S; Srivastava, AK; Tiwari, P1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Maurya, R; Singh, AB; Srivastava, AK1
Narender, T; Papi Reddy, K; Puri, A; Singh, AB; Srivastava, AK1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Glen, RC; Lowe, R; Mitchell, JB1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Dwivedi, AK; Nath, C; Pratap, R; Raghubir, R; Satyanarayana, M; Singh, AB; Singh, H; Singh, SK; Srivastava, AK; Srivastava, M; Srivastava, SP; Tiwari, P; Verma, AK1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Tuomilehto, J1
Alvarez Fidalgo, P; Codoceo, R; Díez, JJ; Iglesias, P1
Athyros, VG; Elisaf, M; Mikhailidis, DP1
Bauer, MF; Francesconi, C; Hohenecker, J; Ledl, M; Roden, M; Roots, I1
Guo, XH; Wang, NH; Wang, W; Wu, HH; Xu, XS1
Guo, XH; Wang, NH; Wang, W1
Kastelein, JJ; Nieuwdorp, M; Stroes, ES1
Abdallah, P; Basset, A; Beylot, M; Bricca, G; Del Carmine, P; Forcheron, F; Metais, C1
Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A1
Dieterich, HA; Dole, WP; Howard, D; Maboudian, M; Vaidyanathan, S; Warren, V; Yeh, CM1
Abdallah, P; Basset, A; Beylot, M; Del Carmine, P; Forcheron, F; Gadot, N1
Krysiak, R; Okopien, B; Pruski, M1
Al-Mousawi, AM; Gauglitz, GG; Herndon, DN; Jeschke, MG; Mecott, GA1
Abdallah, P; Basset, A; Beylot, M; del Carmine, P; Forcheron, F; Haffar, G1
Basset, A; Beylot, M; Del Carmine, P; Forcheron, F1
Aslanidis, C; Bauer, S; Buechler, C; Luchner, A; Neumeier, M; Schäffler, A; Schnitzbauer, AA; Wanninger, J; Weigert, J1
Feng, L; Gao, G; Gao, L; Guan, Q; Liu, Y; Wan, Q; Wang, C; Wang, F; Zhao, J1
Bundrick, JB; Litin, SC1
Gdula-Dymek, A; Krysiak, R; Okopien, B4
Colman, PG; Donoghoe, M; Forder, P; Graham, N; Haapamäki, H; Keech, A; Kritharides, L; Merrifield, A; Simes, J; Sullivan, D; Whiting, M1
Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN1
Rehman, HU1
Cho, YM; Kang, GH; Oh, TJ; Park, KS; Shin, JY1
Arnett, TR; Butters, OR; Patel, JJ1
Lee, WL; Loo, SC; Tan, CN; Tan, JW1
Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M1
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N1
Anabtawi, A; Miles, JM; Moriarty, PM1
Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A1

Reviews

4 review(s) available for metformin and fenofibrate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
    Diabetes research and clinical practice, 2003, Volume: 61 Suppl 1

    Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2003
The role of hyperglycemia in burned patients: evidence-based studies.
    Shock (Augusta, Ga.), 2010, Volume: 33, Issue:1

    Topics: Blood Glucose; Burns; Fenofibrate; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin

2010
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
    Current cardiology reports, 2017, Volume: 19, Issue:7

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metformin; Pioglitazone; Thiazolidinediones

2017

Trials

10 trial(s) available for metformin and fenofibrate

ArticleYear
Inflammatory markers and the metabolic syndrome.
    Atherosclerosis, 2005, Volume: 183, Issue:1

    Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome

2005
Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:6

    Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Treatment Outcome

2007
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
    Diabetes care, 2009, Volume: 32, Issue:8

    Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibrinogen; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Placebos; Plasminogen Activator Inhibitor 1; Risk Factors

2009
Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial.
    Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:11

    Topics: Adolescent; Adult; Aged; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Prediabetic State; Young Adult

2010
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
    The American journal of cardiology, 2011, Apr-01, Volume: 107, Issue:7

    Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Lymphocytes; Male; Metformin; Middle Aged; Monocytes; Prospective Studies; Simvastatin; Systemic Inflammatory Response Syndrome

2011
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
    Diabetes research and clinical practice, 2011, Volume: 94, Issue:2

    Topics: Administration, Oral; Aged; Australia; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome

2011
Combination therapy with metformin and fenofibrate for insulin resistance in obesity.
    The Journal of international medical research, 2011, Volume: 39, Issue:5

    Topics: Adult; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperinsulinism; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Treatment Outcome; Young Adult

2011
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:1

    Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intolerance; Hemostasis; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Prediabetic State; Single-Blind Method

2013
Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:2

    Topics: Anti-Inflammatory Agents; C-Reactive Protein; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Intercellular Adhesion Molecule-1; Lipids; Lymphocytes; Male; Metformin; Middle Aged

2013
Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:5

    Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Female; Fenofibrate; Glucose Intolerance; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Lipids; Male; Metformin; Middle Aged; Monocytes; Poland; Time Factors; Treatment Outcome; Young Adult

2013

Other Studies

31 other study(ies) available for metformin and fenofibrate

ArticleYear
Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.
    Bioorganic & medicinal chemistry letters, 2007, Mar-15, Volume: 17, Issue:6

    Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Aegle; Animals; Blood Glucose; Cholesterol; Cholesterol, HDL; Cricetinae; Diabetes Mellitus, Experimental; Dietary Fats; Fatty Acids, Nonesterified; Hypoglycemic Agents; Hypolipidemic Agents; Male; Models, Molecular; Phospholipids; Rats; Rats, Sprague-Dawley; Triglycerides

2007
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.
    Bioorganic & medicinal chemistry letters, 2008, Dec-15, Volume: 18, Issue:24

    Topics: Animals; Chemistry, Pharmaceutical; Diabetes Mellitus, Experimental; Hyperglycemia; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Metformin; Mice; Mice, Inbred C57BL; Plant Extracts; Rats; Rats, Sprague-Dawley; Withania; Withanolides

2008
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
    Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15

    Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemistry, Pharmaceutical; Cricetinae; Diabetes Mellitus, Experimental; Drug Design; Glucose; Hypoglycemic Agents; Hypolipidemic Agents; Models, Chemical; Pentacyclic Triterpenes; Rats; Streptozocin; Triglycerides; Triterpenes

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Flavone-based novel antidiabetic and antidyslipidemic agents.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Animals; Biological Availability; Cholesterol; Cricetinae; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Flavones; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Streptozocin; Structure-Activity Relationship; Triglycerides

2012
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations.
    Endocrine journal, 2004, Volume: 51, Issue:3

    Topics: Adiponectin; Aged; Blood Glucose; Cytokines; Diabetes Mellitus, Lipoatrophic; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hormones, Ectopic; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Leptin; Metformin; Resistin; Tumor Necrosis Factor-alpha; Weight Loss

2004
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
    Diabetologia, 2005, Volume: 48, Issue:10

    Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Muscular Diseases; Rosiglitazone; Thiazolidinediones

2005
[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2006, Apr-18, Volume: 38, Issue:2

    Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Kidney; Lipid Metabolism; Metformin; Rats; Rats, Inbred OLETF; Sterol Regulatory Element Binding Protein 1

2006
[Change in ghrelin level with the amelioration of glucose and lipid metabolic disorder in OLETF rats].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2006, Dec-18, Volume: 38, Issue:6

    Topics: Animals; Blotting, Northern; Diabetes Mellitus, Type 2; Fenofibrate; Gastric Mucosa; Ghrelin; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Random Allocation; Rats; Rats, Inbred OLETF; RNA, Messenger; Stomach

2006
Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.
    Metabolism: clinical and experimental, 2008, Volume: 57, Issue:7

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Eating; Fatty Acids, Nonesterified; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; PPAR alpha; Rats; Rats, Zucker; Receptors, Adiponectin; RNA, Messenger; Triglycerides

2008
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
    The Journal of pharmacy and pharmacology, 2008, Volume: 60, Issue:9

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides

2008
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Current medical research and opinion, 2008, Volume: 24, Issue:8

    Topics: Adolescent; Adult; Amides; Antihypertensive Agents; Area Under Curve; Chromatography, Liquid; Drug Interactions; Female; Fenofibrate; Fumarates; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Renin; Tandem Mass Spectrometry; Thiazolidinediones

2008
Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat.
    Cardiovascular diabetology, 2009, Mar-24, Volume: 8

    Topics: Animals; Blood Glucose; Cardiomyopathies; Diabetes Mellitus, Experimental; Disease Models, Animal; Fenofibrate; Male; Metformin; Rats; Rats, Zucker

2009
Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:7

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Eating; Energy Metabolism; Fatty Acids; Fatty Liver; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; PPAR alpha; Rats; Rats, Zucker; RNA, Messenger; Triglycerides

2009
Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
    Diabetes & metabolism, 2009, Volume: 35, Issue:6

    Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Nonesterified; Fenofibrate; Heart; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Male; Membrane Proteins; Metformin; Myocardium; Obesity; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triglycerides

2009
Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals.
    Archives of medical research, 2010, Volume: 41, Issue:2

    Topics: 3T3-L1 Cells; Adipocytes; Aged; Animals; Diabetes Mellitus; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Intra-Abdominal Fat; Male; Metformin; Mice; Middle Aged; Rats; Rats, Zucker; Receptors, Adiponectin

2010
Clinical pearls in general internal medicine.
    Mayo Clinic proceedings, 2011, Volume: 86, Issue:1

    Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Infective Agents, Urinary; Antihypertensive Agents; Calcium Channel Blockers; Creatinine; Diagnosis, Differential; Female; Fenofibrate; Gout; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Internal Medicine; Losartan; Male; Metformin; Nifedipine; Potassium; Sulfonamides; Tamsulosin; Trimethoprim; Ureteral Calculi; Vitamin B 12 Deficiency

2011
The work-up for mixed hyperlipidemia: a case study.
    The Journal of family practice, 2012, Volume: 61, Issue:3

    Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Male; Metformin; Physical Examination; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2012
Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
    Experimental & molecular medicine, 2013, Jul-05, Volume: 45

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exenatide; Feeding Behavior; Fenofibrate; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Tolerance Test; Homeostasis; Immunohistochemistry; Injections, Intraperitoneal; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Peptides; Rats; Receptors, Glucagon; Venoms

2013
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
    Cell biochemistry and function, 2014, Volume: 32, Issue:4

    Topics: Adipogenesis; Animals; Cell Differentiation; Cells, Cultured; Chromans; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Droplets; Metformin; Mice; Osteoblasts; Osteoclasts; Osteogenesis; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Troglitazone

2014
Modulating drug release from gastric-floating microcapsules through spray-coating layers.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Capsules; Coated Materials, Biocompatible; Delayed-Action Preparations; Fenofibrate; Half-Life; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Piroxicam

2014
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
    Journal of pediatric endocrinology & metabolism : JPEM, 2015, Volume: 28, Issue:1-2

    Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Glucose Intolerance; Humans; Infant; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Metabolome; Metformin; Pituitary Neoplasms; Retrospective Studies

2015
Reducing CV risk in diabetes: An ADA update.
    The Journal of family practice, 2017, Volume: 66, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones

2017
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
    PloS one, 2022, Volume: 17, Issue:9

    Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Insulin; Liraglutide; Male; Metformin; Obesity; Ramipril; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosuvastatin Calcium; Somatostatin

2022